Cancer datasets and tissue pathways

The College's Datasets for Histopathological Reporting on Cancers are vital for standardising cancer reporting methods among pathologists. These datasets define the range of acceptable practice in handling pathology specimens, and enhance cancer diagnosis and treatment quality. 

Cancer datasets encompass structured collections of data related to cancer patients. Tissue pathways are instrumental in defining best practices when handling pathology specimens from patients who do not have cancer. These guidelines are pivotal in raising the bar for healthcare standards in pathology.

TNM 9 is to be implemented in most specialties for patients diagnosed on or after 1 January 2026. A full list of staging systems to be used (by specialty) is available in the Recommendations from the Recommendation on the use of tumour staging systems from the College’s Working Group on Cancer Services. See below for the full list of staging recommendations for each specialty. 

The updated TNM 9 staging appendices are now available accompanying the datasets below.

Breast

 

Endocrine system

 

Eye

 

Gastrointestinal tract

Liver

 

 

 

Gynaecological tract

Head and neck

Nodal excisions & neck dissection

November 2013

We would like to inform you that while this guideline has previously undergone consultation, it will not be published in its current form. The guideline is being reviewed again following the release of the new ICCR, as it is essential to ensure it aligns with our core data requirements.

Due to the comprehensive nature of this review, which involves a complete revision and rewrite of the content, the guideline will need to go through all stages of consultation and approval again, effectively starting the process from the beginning.

We appreciate your understanding and patience as we work to deliver a high-quality, evidence-based guideline that meets the latest standards.

 

Lung and thorax

Tissue pathway for non-neoplastic thoracic pathology

October 2024

 

 

Skin

Invasive squamous cell carcinoma

 

 

Urinary tract and testis